Study of niraparib for advanced ovarian cancer after chemo
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial is testing a medication called niraparib (Zejula) for women with advanced or relapsed ovarian cancer. It may help keep the cancer from coming back after it has responded to platinum-based chemotherapy. The study focuses on safety and is for women who meet certain health and treatment criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with a type of ovarian cancer called epithelial ovarian cancer, and it has either spread or come back after treatment.
- Your cancer has responded (shrunk or gone away) after platinum-based chemotherapy (like carboplatin or cisplatin).
- Your blood counts (white cells, red cells, and platelets) are at healthy levels.
- You are not pregnant, breastfeeding, and will use birth control during the study and for 180 days after the last dose.
- You have not had a PARP inhibitor (like Lynparza, Rubraca, or Zejula) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at continuing niraparib for a longer time in people who already finished an earlier niraparib trial and are still benefiting. It may help understand how safe and useful long-term treatment is for you.
This study looks for proteins in your blood that might show if niraparib maintenance therapy works well after first platinum chemo. It helps doctors personalize treatment for advanced ovarian cancer.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
This trial tests whether the PARP inhibitor niraparib can help keep advanced ovarian cancer from coming back. You may qualify if you have a BRCA mutation or HRD-positive tumor and finished first-line chemotherapy with bevacizumab (Avastin) with good response.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.